Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphism

Debojoyti Ghosh, Amrita Panja, Dipankar Saha, Uma Banerjee, Asok Kumar Dutta, Anupam Basu
doi: https://doi.org/10.1101/2021.02.28.21251843

Article Information

doi 
https://doi.org/10.1101/2021.02.28.21251843
History 
  • March 1, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Debojoyti Ghosh1,2,#,
  2. Amrita Panja2,#,
  3. Dipankar Saha2,
  4. Uma Banerjee1,
  5. Asok Kumar Dutta3,& and
  6. Anupam Basu2,*
  1. 1Department of Pathology, Burdwan Medical College and Hospital, Burdwan, West Bengal, India
  2. 2Molecular Biology and Human Genetics Laboratory, Department of Zoology, The University of Burdwan, West Bengal, India
  3. 3Department of Paediatric Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India
  1. ↵*Corresponding Author: E-mail address: abasu{at}zoo.buruniv.ac.in
  2. ↵&Co-Corresponding Author: Asok Kumar Dutta (e-mail: asokdutta31{at}yahoo.com)

  1. ↵# These authors contributed equally to this work and are considered to be co-first authors

Back to top
Posted March 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphism
Debojoyti Ghosh, Amrita Panja, Dipankar Saha, Uma Banerjee, Asok Kumar Dutta, Anupam Basu
medRxiv 2021.02.28.21251843; doi: https://doi.org/10.1101/2021.02.28.21251843
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area